Susquehanna International Group, LLP Adaptimmune Therapeutics PLC Transaction History

Susquehanna International Group, LLP

$560 Billion
Q3 2024

A detailed history of Susquehanna International Group, LLP transactions in Adaptimmune Therapeutics PLC stock. As of the latest transaction made, Susquehanna International Group, LLP holds 189,472 shares of ADAP stock, worth $113,683. This represents 0.0% of its overall portfolio holdings.

Number of Shares

189,472

Previous 242,144 21.75%

Holding current value

$113,683

Previous $237,000 24.47%

% of portfolio

0.0%

Previous 0.0%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$0.92 - $1.39 $48,458 - $73,214	-52,672 Reduced 21.75%	189,472 $179,000
Q2 2024 Aug 15, 2024	BUY	$0.83 - $1.47 $154,218 - $273,134	185,806 Added 329.81%	242,144 $237,000
Q1 2024 May 07, 2024	SELL	$0.7 - $1.75 $355 - $889	-508 Reduced 0.89%	56,338 $89,000
Q4 2023 Feb 14, 2024	SELL	$0.43 - $0.79 $47,318 - $86,933	-110,042 Reduced 65.94%	56,846 $44,000
Q3 2023 Nov 14, 2023	SELL	$0.73 - $1.04 $10,739 - $15,300	-14,712 Reduced 8.1%	166,888 $130,000
Q2 2023 Aug 11, 2023	BUY	$0.9 - $1.51 $163,440 - $274,216	181,600 New	181,600 $167,000
Q4 2022 Feb 14, 2023	BUY	$1.05 - $2.53 $29,532 - $71,158	28,126 New	28,126 $41,000
Q2 2022 Aug 15, 2022	BUY	$1.33 - $2.28 $72,890 - $124,955	54,805 Added 68.41%	134,912 $229,000
Q1 2022 May 16, 2022	SELL	$1.73 - $4.06 $55,327 - $129,842	-31,981 Reduced 28.53%	80,107 $165,000
Q4 2021 Feb 14, 2022	SELL	$3.5 - $5.68 $389,641 - $632,331	-111,326 Reduced 49.83%	112,088 $420,000
Q3 2021 Nov 15, 2021	BUY	$3.44 - $6.37 $389,421 - $721,109	113,204 Added 102.72%	223,414 $1.16 Million
Q2 2021 Aug 11, 2021	BUY	$3.86 - $5.78 $228,380 - $341,979	59,166 Added 115.91%	110,210 $469,000
Q1 2021 May 17, 2021	SELL	$4.9 - $6.83 $474,109 - $660,850	-96,757 Reduced 65.46%	51,044 $271,000
Q4 2020 Feb 16, 2021	BUY	$4.0 - $9.2 $591,204 - $1.36 Million	147,801 New	147,801 $796,000
Q4 2018 Feb 14, 2019	SELL	$3.76 - $14.16 $243,508 - $917,044	-64,763 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$8.27 - $13.56 $85,660 - $140,454	10,358 Added 19.04%	64,763 $878,000
Q1 2018 May 15, 2018	BUY	$7.1 - $11.56 $386,275 - $628,921	54,405 New	54,405 $611,000

Others Institutions Holding ADAP

# of Institutions

Shares Held

150M

Call Options Held

60.8K

Put Options Held

5.8K

View Full List

About Adaptimmune Therapeutics PLC

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $98M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

More about ADAP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account

Susquehanna International Group, LLP Adaptimmune Therapeutics PLC Transaction History